KFA Private Wealth Group LLC Sells 143 Shares of Johnson & Johnson (NYSE:JNJ)

by · The Cerbat Gem

KFA Private Wealth Group LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,501 shares of the company’s stock after selling 143 shares during the period. KFA Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $405,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of JNJ. Shilanski & Associates Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $427,000. Dakota Community Bank & Trust NA raised its position in shares of Johnson & Johnson by 20.6% in the 1st quarter. Dakota Community Bank & Trust NA now owns 1,498 shares of the company’s stock worth $237,000 after purchasing an additional 256 shares during the last quarter. Allied Investment Advisors LLC raised its position in shares of Johnson & Johnson by 4.5% in the 1st quarter. Allied Investment Advisors LLC now owns 57,045 shares of the company’s stock worth $9,024,000 after purchasing an additional 2,431 shares during the last quarter. Aurora Investment Managers LLC. raised its position in shares of Johnson & Johnson by 3.5% in the 1st quarter. Aurora Investment Managers LLC. now owns 3,745 shares of the company’s stock worth $592,000 after purchasing an additional 125 shares during the last quarter. Finally, Tealwood Asset Management Inc. raised its position in shares of Johnson & Johnson by 1.0% in the 1st quarter. Tealwood Asset Management Inc. now owns 15,634 shares of the company’s stock worth $2,473,000 after purchasing an additional 148 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Citigroup boosted their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $175.93.

View Our Latest Analysis on JNJ

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 0.4 %

Johnson & Johnson stock opened at $165.12 on Friday. The business has a 50-day simple moving average of $162.98 and a two-hundred day simple moving average of $154.69. The company has a market cap of $397.39 billion, a P/E ratio of 10.29, a P/E/G ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the company posted $2.66 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.00%. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).